J&J sees deal ‘opportunities’ in neuroscience and immunology post-Ambrx buy Sanofi inks $1.7B Inhibrx buyout, snagging rare disease drug but spinning out cancer programs Novo Nordisk puts $255M on the line to bag another obesity asset, turning to EraCal for novel approach Merck & Co. signs $220M macrocyclic peptide deal after hailing ‘next wave of drug discovery’ Two more pharmas practice their Accent, invest in $75M series C round Another big pharma competed for Karuna, submitting all-cash offer day before BMS deal announcement Roche's Genentech spends $15M to rocket into GenEdit’s NanoGalaxy NAYA buys Florida Biotechnologies for $20M to get hold of rare genetic disease drug Fierce Biotech Fundraising Tracker '24: Calluna launches with $81M; Accent adds on $75M |